Hyperphosphatemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for hyperphosphatemia. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
2
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Hyperphosphatemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Keryx Biopharms 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating hyperphosphatemia. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Auryxia
FERRIC CITRATE
 Keryx Biopharms 2 62 — 2030-07-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10300039 Auryxia method of use 68 2030-07-21
9387191 Auryxia formulation 48 2030-07-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9387191 Auryxia formulation 48 2030-07-21
10300039 Auryxia method of use 68 2030-07-21

Related